Compositions and methods for the treatment of motion sickness and emesis

An intranasal pharmaceutical composition for use in a human subject comprising a therapeutically effective amount of scopolamine or a pharmaceutically acceptable salt thereof at a concentration of from about 0.15% (w/w) to about 0.18% (w/w), wherein the composition is capable of prevention of, or rescue from, one or more of nausea or vomiting related to motion in a human subject, wherein when the composition is administered to a subject, the composition is capable of exhibiting an AUC for unbound scopolamine or a pharmaceutically acceptable salt thereof that is approximately 40% lower than unbound scopolamine or a pharmaceutically acceptable salt thereof for transdermal administration, wherein the composition is capable of an approximately equivalent Cmax for unbound scopolamine or a pharmaceutically acceptable salt thereof as compared to transdermal administration of scopolamine or a pharmaceutically acceptable salt thereof, and wherein the composition has a viscosity of at about 1750 to about 3500 centistokes.